{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:39:57Z","timestamp":1793637597279,"version":"4.5.1"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Breast cancer (BC) remains one of the most prevalent malignancies worldwide, with approximately 70% of cases being estrogen receptor-positive (ER+). Endocrine therapy targeting the estrogen receptor has revolutionized BC treatment, evolving from surgical oophorectomy to selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs). Selective estrogen receptor degraders (SERDs) represent the latest advancement in hormonal therapy, offering complete receptor blockade and degradation. This review comprehensively examines the mechanisms of SERD action, their role in overcoming resistance to conventional endocrine therapy, and clinical applications of approved agents including fulvestrant, elacestrant, imlunestrant, and vepdegestrant, the first FDA-approved PROTAC estrogen receptor degrader. We discuss emerging oral SERDs such as giredestrant and camizestrant, novel PROTAC-based approaches, and combination strategies with CDK4\/6 inhibitors, PI3K inhibitors, and other targeted agents. Special attention is given to ESR1 mutations as biomarkers for patient selection and therapy optimization. The review highlights key clinical trials including EMERALD, EMBER-3, SERENA-6, and lidERA that have shaped current treatment guidelines and points toward future directions in SERD development.<\/jats:p>","DOI":"10.3389\/fonc.2026.1855542","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:58:06Z","timestamp":1786355886000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Anton Yu","family":"Alasheev","sequence":"first","affiliation":[{"name":"Institute of Future Biophysics, Moscow Institute of Physics and Technology","place":["Dolgoprudny, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raneem","family":"Hamama","sequence":"additional","affiliation":[{"name":"Institute of Future Biophysics, Moscow Institute of Physics and Technology","place":["Dolgoprudny, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Petersen","sequence":"additional","affiliation":[{"name":"Institute of Future Biophysics, Moscow Institute of Physics and Technology","place":["Dolgoprudny, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp Y.","family":"Maximov","sequence":"additional","affiliation":[{"name":"Institute of Future Biophysics, Moscow Institute of Physics and Technology","place":["Dolgoprudny, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"73","author":"Sung","year":"2023","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/d41586-024-01425-6","article-title":"Innovative cancer therapies offer new hope","volume":"629","author":"Brody","year":"2024","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp Mol Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2025.2483818","article-title":"Discovery and development of steroidal enzyme inhibitors as anti-cancer drugs: state-of-the-art and future perspectives","volume":"40","author":"Cerra","year":"2025","journal-title":"J Enzyme Inhib Med Chem"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35073","article-title":"Trends in breast cancer incidence by estrogen receptor status in the United States, 2004\u20132020","volume":"155","author":"Jiang","year":"2024","journal-title":"Int J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194689","article-title":"Estrogen receptor signaling in breast cancer","volume":"15","author":"Miziak","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030619","article-title":"Oral SERD, a novel endocrine therapy for estrogen receptor-positive breast cancer","volume":"16","author":"Neupane","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1042\/ebc20200167","article-title":"The physiological role of estrogen receptor functional domains","volume":"65","author":"Arao","year":"2021","journal-title":"Essays Biochem"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","article-title":"Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment","volume":"186","author":"Patel","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/39645","article-title":"Molecular basis of agonism and antagonism in the oestrogen receptor","volume":"389","author":"Brzozowski","year":"1997","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.12792","article-title":"Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation","volume":"5","author":"Fanning","year":"2016","journal-title":"eLife"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1159\/000160910","article-title":"Endocrine therapy \u2014 what else","volume":"3","author":"Marth","year":"2008","journal-title":"Breast Care (Basel)"},{"key":"B14","article-title":"The results of adrenalectomy in advanced breast cancer in 500 consecutive patients","volume":"125","author":"Fracchia","year":"1967","journal-title":"Surg Gynecol Obstet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-395541-8.50013-6","article-title":"Estrogen-receptor interactions in target tissues","volume":"56","author":"Jensen","year":"1967","journal-title":"Arch Anat Microsc Morphol Exp"},{"key":"B16","article-title":"The story of hormonal therapy in breast cancer \u2013 and an important drug in oncology history, tamoxifen","volume-title":"Oncopedia","author":"Fricker","year":""},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Robertson","year":"2005","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"B19","article-title":"Aromatase inhibitors are better than tamoxifen at reducing the risk of breast cancer recurrence in premenopausal as well as postmenopausal women","author":"Johnston","year":"","journal-title":"Nuffield Department of Population Health"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial","volume":"26","author":"Eastell","year":"2008","journal-title":"J Clin Oncol"},{"key":"B21","article-title":"The study of tamoxifen and raloxifene (STAR): questions and answers","volume-title":"National Cancer Institute","year":"2006"},{"key":"B22","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: Preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01208-8","article-title":"Advances in endocrine-based therapies for estrogen receptor-positive metastatic breast cancer","volume":"79","author":"Aggelis","year":"2019","journal-title":"Drugs"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-022-10066-y","article-title":"The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options","volume":"41","author":"Wang","year":"2022","journal-title":"Cancer Metastasis Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221113694","article-title":"Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role","volume":"14","author":"Lloyd","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B26","unstructured":"SERENA-2 trial: camizestrant improves progression-free survival in advanced breast cancer\n          \n          \n            \n              Helwick\n              C\n            \n          \n          The Asco Post\n          \n          2023"},{"key":"B27","unstructured":"FASLODEX\u00ae (fulvestrant) injection, for intramuscular use: prescribing information\n          \n          \n          \n          2019"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1136","article-title":"Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study","volume":"27","author":"Robertson","year":"2009","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.8415","article-title":"Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer","volume":"28","author":"Di Leo","year":"2010","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet"},{"key":"B31","unstructured":"FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer\n          \n          \n          American Society of Clinical Oncology (ASCO)\n          \n          2023"},{"key":"B32","article-title":"Elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","volume-title":"The Asco Post","author":"Stenger","year":"2023"},{"key":"B33","article-title":"FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","volume-title":"Fda","year":"2025"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"B35","article-title":"Updated data for Lilly's Inluriyo (imlunestrant) reinforce efficacy results in ER+, HER2- advanced breast cancer","volume-title":"Press Release","year":"2025"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00136","article-title":"Targeting the estrogen receptor for the treatment of breast cancer: recent advances and challenges","volume":"66","author":"Rej","year":"2023","journal-title":"J Med Chem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ Breast cancer models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B38","unstructured":"Updated clinical data from Phase 1b\/2 VERITAC study of vepdegestrant\n          \n          \n          \n          2024"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer","volume":"393","author":"Hamilton","year":"2025","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01818","article-title":"NDA submission of vepdegestrant (ARV-471) to U.S. FDA: the beginning of a new era of PROTAC degraders","volume":"68","author":"Ma","year":"2025","journal-title":"J Med Chem"},{"key":"B41","article-title":"FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","volume-title":"Fda","year":"2026"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02746","article-title":"AMEERA-3: randomized phase II study of amcenestrant (Oral selective estrogen receptor degrader) versus standard endocrine monotherapy in estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer","volume":"41","author":"Tolaney","year":"2023","journal-title":"J Clin Oncol"},{"key":"B43","unstructured":"Positive phase III results show Roche's giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer (evERA)\n          \n          \n          \n          2025"},{"key":"B44","unstructured":"evERA Breast Cancer Phase III results: giredestrant plus everolimus demonstrates statistically significant improvement in progression-free survival\n          \n          \n          \n          2025"},{"key":"B45","unstructured":"Giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer (lidERA)\n          \n          \n          \n          2025"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01500","article-title":"Giredestrant for estrogen receptor\u2013positive, HER2-negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA breast cancer study","volume":"42","author":"Mart\u00edn","year":"2024","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00268-1","article-title":"Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study","volume":"24","author":"Hurvitz","year":"2023","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol"},{"key":"B49","article-title":"SERENA-2: Camizestrant vs Fulvestrant in Advanced ER+\/HER2- Breast Cancer","volume-title":"Onclive","author":"Kalinsky","year":"2024"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(26)00287-1","article-title":"Camizestrant plus a CDK4\/6 inhibitor versus continued aromatase inhibitor plus CDK4\/6 inhibitor upon ctDNA detection of an emergent ESR1 mutation during first-line therapy (SERENA-6): a phase III, double-blind, ctDNA-guided switch trial","volume":"83","author":"Turner","year":"2025","journal-title":"N Engl J Med"},{"key":"B51","unstructured":"Camizestrant Reduced the Risk of Disease Progression or Death by 56% in Patients With Advanced HR-Positive Breast Cancer With an Emergent ESR1 Tumour Mutation in SERENA-6 Phase III Trial\n          \n          2025"},{"key":"B52","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.MCT-21-0378","article-title":"Covalent ER\u03b1 antagonist H3B-6545 demonstrates encouraging preclinical activity in therapy-resistant breast cancer","volume":"21","author":"Furman","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.05.005","article-title":"Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c00855","article-title":"Discovery of an orally bioavailable and brain penetrant selective estrogen receptor degrader","volume":"68","author":"Zhang","year":"2025","journal-title":"J Med Chem"},{"key":"B55","article-title":"Elacestrant-based combinations show efficacy and safety in ER+\/HER2-negative breast cancer: ELEVATE trial results","volume-title":"Sabcs 2025","author":"Rugo","year":""},{"key":"B56","unstructured":"Phase III Study ADELA: Elacestrant With Everolimus for Advanced Breast Cancer\n          \n          2024"},{"key":"B57","unstructured":"ELEGANT: Elacestrant Versus Standard Endocrine Therapy in Adjuvant Setting for ER+\/HER2- Early Breast Cancer\n          \n          2024"},{"key":"B58","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamaoncol.2022.7949","article-title":"Evaluation of Alisertib alone or combined with Fulvestrant in patients with endocrine-resistant advanced breast cancer: The Phase 2 TBCRC041 randomized clinical trial","volume":"9","author":"Haddad","year":"2023","journal-title":"JAMA Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00443-1","article-title":"The state of the science of oral selective oestrogen receptor degraders","volume":"25","author":"Bidard","year":"2024","journal-title":"Lancet Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41523-023-00533-2","article-title":"Estrogen\/HER2 receptor crosstalk in breast cancer: Combination therapies to improve outcomes for patients with hormone receptor-positive\/HER2-positive breast cancer","volume":"9","author":"Pegram","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/1097-0142(195901\/02)12:1<85::aid-cncr2820120114>3.0.co;2-g","article-title":"Results of hypophysectomy in the treatment of metastatic mammary carcinoma","volume":"12","author":"Pearson","year":"1959","journal-title":"Cancer"}],"updated-by":[{"DOI":"10.3389\/fonc.2026.1986541","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1855542\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:49:40Z","timestamp":1790840980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1855542\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":61,"alternative-id":["10.3389\/fonc.2026.1855542"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1855542","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1855542"}}